NEUROBIOLOGY AND DESIPRAMINE IN BULIMIA

暴食症的神经生物学和地昔帕明

• 批准号: 3902434
• 负责人: ALAN B. LEVY
• 金额: --
• 依托单位: OHIO STATE UNIVERSITY
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3902434
• 关键词: antidepressants; bulimia nervosa; cortisol; desipramine; drug metabolism; endocrine disorder; hormone regulation /control mechanism; human subject; human therapy evaluation; mental disorder chemotherapy; neuroendocrine system; nutrition disorder chemotherapy; placebos; prolactin; psychophysiology; thyrotropin releasing hormone

Recent evidence suggests patients with bulimia respond to desipramine therapy. Forty bulimics will be treated either with desipramine, or placebo while controlling for concurrent depression. Hormonal responses (TRH-stim for TSH, GH, and PRL and DST for cortisol, ACTH and beta endorphin), will also be evaluated to determine if neuroendocrine abnormalities initially present in bulimics will normalize with therapy.

最近的证据表明，暴食症患者对 地昔帕明治疗 40名暴食症患者将接受 地昔帕明或安慰剂，同时控制并发 萧条 激素反应（促甲状腺激素释放激素刺激促甲状腺激素、生长激素和泌乳素， 皮质醇、ACTH和β内啡肽的DST），也将进行评估 以确定是否神经内分泌异常最初存在于 暴食症会通过治疗恢复正常